WO2005114212A3 - Diagnostics et therapies pour maladies associees au recepteur npy4 couple a la proteine g - Google Patents

Diagnostics et therapies pour maladies associees au recepteur npy4 couple a la proteine g Download PDF

Info

Publication number
WO2005114212A3
WO2005114212A3 PCT/EP2005/004905 EP2005004905W WO2005114212A3 WO 2005114212 A3 WO2005114212 A3 WO 2005114212A3 EP 2005004905 W EP2005004905 W EP 2005004905W WO 2005114212 A3 WO2005114212 A3 WO 2005114212A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
npy4
diseases
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/004905
Other languages
English (en)
Other versions
WO2005114212A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2005114212A2 publication Critical patent/WO2005114212A2/fr
Publication of WO2005114212A3 publication Critical patent/WO2005114212A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un récepteur humain NPY4 qui est associé aux maladies gastro-intestinales et aux maladies du foie, aux maladies cardio-vasculaires, aux maladies métaboliques, aux maladies inflammatoires, aux troubles hématologiques, aux maladies respiratoires, aux troubles neurologiques, aux troubles de la reproduction et aux troubles urologiques. L'invention porte également sur des essais pour identifier des composés utiles dans le traitement ou la prévention des maladies gastro-intestinales et du foie, des maladies cardio-vasculaires, des maladies métaboliques, des maladies inflammatoires, des troubles hématologiques, des maladies respiratoires, des troubles neurologiques, des troubles de la reproduction et des troubles urologiques. L'invention porte aussi sur des composés qui se lient et/ou activent ou inhibent l'activité de NPY4, ainsi que sur des compositions pharmaceutiques comprenant ces composés.
PCT/EP2005/004905 2004-05-21 2005-05-06 Diagnostics et therapies pour maladies associees au recepteur npy4 couple a la proteine g WO2005114212A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04012037 2004-05-21
EP04012037.0 2004-05-21

Publications (2)

Publication Number Publication Date
WO2005114212A2 WO2005114212A2 (fr) 2005-12-01
WO2005114212A3 true WO2005114212A3 (fr) 2006-02-02

Family

ID=34969114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004905 WO2005114212A2 (fr) 2004-05-21 2005-05-06 Diagnostics et therapies pour maladies associees au recepteur npy4 couple a la proteine g

Country Status (1)

Country Link
WO (1) WO2005114212A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1403380A1 (fr) * 2002-09-27 2004-03-31 Integragen Gène humain de susceptibilité à l'obésité et leurs utilisations
US6734166B1 (en) * 2000-02-08 2004-05-11 North Carolina State University Method of reducing aluminum levels in the central nervous system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734166B1 (en) * 2000-02-08 2004-05-11 North Carolina State University Method of reducing aluminum levels in the central nervous system
EP1403380A1 (fr) * 2002-09-27 2004-03-31 Integragen Gène humain de susceptibilité à l'obésité et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERGLUND MAGNUS M ET AL: "Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes.", EXPERIMENTAL BIOLOGY AND MEDICINE (MAYWOOD), vol. 228, no. 3, March 2003 (2003-03-01), pages 217 - 244, XP002344960, ISSN: 1535-3702 *
PARKER R M C ET AL: "Regional distribution of Y-receptor subtype mRNAs in rat brain", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 11, no. 4, April 1999 (1999-04-01), pages 1431 - 1448, XP002344900, ISSN: 0953-816X *

Also Published As

Publication number Publication date
WO2005114212A2 (fr) 2005-12-01

Similar Documents

Publication Publication Date Title
WO2005106492A3 (fr) Diagnostic et traitement therapeutique des maladies associees au recepteur 3 de la chimiokine c-c (ccr3)
WO2004097421A3 (fr) Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
WO2005095973A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au recepteur 54 couple a la proteine g (gpr54)
WO2005103702A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur 2 de la chimiokine cxc (cxcr2)
WO2005106471A3 (fr) Diagnostics et therapies pour des maladies associees a un recepteur 4 de chimiokine c-c (ccr4)
WO2005095972A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur couple aux proteines g etb (etb)
WO2005040828A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49)
WO2004080373A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 2 active par la proteinase (par2) couple aux proteines g
WO2005050225A3 (fr) Outils de diagnostic et de traitement de maladies associees au recepteur 84 couple aux proteines g (gpr84)
WO2005106489A3 (fr) Diagnostics et therapies s'appliquant a des maladies associees aux recepteurs 5 des chimiokines c-c (ccr5)
WO2004082568A3 (fr) Diagnostics et traitements contre des maladies associees au recepteur 5a du composant du complement (c5ar)
WO2005106488A3 (fr) Diagnostics et therapeutique de maladies associees a l'adrenorecepteur beta-2 couple aux proteines g (adrb2)
WO2005108998A3 (fr) Methodes de diagnostic et de traitement de maladies associees au recepteur couple aux proteines g adrenergique beta-3 (adrb3)
WO2005059546A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35)
WO2005040211A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur 1 couple aux proteines g (gpr1)
WO2005040825A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20)
WO2005114212A3 (fr) Diagnostics et therapies pour maladies associees au recepteur npy4 couple a la proteine g
WO2005103711A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees au recepteur 1 des chimiokines cxc (cxcr1)
WO2005095984A3 (fr) Compositions diagnostiques et therapeutiques pour des maladies associees au recepteur adrenergique alpha 2a couple a la proteine g (adra2a)
WO2004082571A3 (fr) Diagnostics et therapies pour maladies associees au recepteur 86 couple a la proteine g (gpr86)
WO2005040824A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 24 couple a la proteine g (gpr24)
WO2004104577A3 (fr) Approches diagnostiques et therapeutiques des maladies associees au recepteur 5-hydroxytryptamine 4 (5-ht4)(serotonine)
WO2005103690A3 (fr) Diagnostic et therapeutique de maladies associees au recepteur de l'hormone de liberation de la corticotropine 2 (crhr2)
WO2004082572A3 (fr) Diagnostics et therapies pour les maladies associees au recepteur 87 couple a la proteine g (gpr87)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase